Herpesvirus Antiviral Resistance
Database


    • TOP

    Boivin G

    Mutations:

    Mutant Gene Virus Reference
    Q229K UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q229K UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q229K UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E235G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D247N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D247N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D247N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D262N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D262N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D262N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A269V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D284E UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A336T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I341T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N345S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P375L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Y380C UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L394F UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L424V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L424V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L424V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K426R UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V450G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    H465Y UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A473V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V482G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V483A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P488R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P488R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P488R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K500N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K500N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K500N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    A505V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A505V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A505V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V526L UL54 Human betaherpesvirus 5 Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    V526L UL54 Human betaherpesvirus 5 Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    V526L UL54 Human betaherpesvirus 5 Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    C539R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    C539R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    C539R UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    A543S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A543S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A543S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    T552N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    T552N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    T552N UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    R581H UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S585A UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    S585A UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    S585A UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    F595I UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    F595I UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    F595I UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P617S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P628A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V634A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S651E UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G653S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G667N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G667N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G667N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F718L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F718S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V787E UL54 Human betaherpesvirus 5 Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    V787E UL54 Human betaherpesvirus 5 Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    V787E UL54 Human betaherpesvirus 5 Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. (Sep 2019)
    E793V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E793V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E793V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    R800C UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L802V UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L802V UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L802V UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    G822D UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M828V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P829S UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P829S UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    P829S UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    G841S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G841S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G841S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    R847H UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N855D UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L862F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L862F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L862F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    H863R UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    T892I UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V902G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V902G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V902G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E903G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G920S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V927M UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V946L UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    V946L UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    V946L UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    K947E UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K947E UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K947E UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L957F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L957F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    L957F UL54 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. (Sep 2011)
    M959T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M959T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M959T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S1000L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D1005N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    R1006C UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A427V UL97 Human betaherpesvirus 5 Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    V466G UL97 Human betaherpesvirus 5 Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. (Apr 2010)
    R476C UL97 Human betaherpesvirus 5 Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    M550I UL97 Human betaherpesvirus 5 Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    A582V UL97 Human betaherpesvirus 5 Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    A594T UL97 Human betaherpesvirus 5 Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997)
    A594T UL97 Human betaherpesvirus 5 Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997)
    E596del UL97 Human betaherpesvirus 5 Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. ( 2009)
    K599E UL97 Human betaherpesvirus 5 Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. ( 2009)
    C607F UL97 Human betaherpesvirus 5 Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. (Dec 2001)
    C607Y UL97 Human betaherpesvirus 5 Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. (Dec 2001)
    Y617H UL97 Human betaherpesvirus 5 Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    E655K UL97 Human betaherpesvirus 5 Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    A674T UL97 Human betaherpesvirus 5 Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)